CN1199950C - 作为抗炎剂的喹啉衍生物 - Google Patents

作为抗炎剂的喹啉衍生物 Download PDF

Info

Publication number
CN1199950C
CN1199950C CNB018163513A CN01816351A CN1199950C CN 1199950 C CN1199950 C CN 1199950C CN B018163513 A CNB018163513 A CN B018163513A CN 01816351 A CN01816351 A CN 01816351A CN 1199950 C CN1199950 C CN 1199950C
Authority
CN
China
Prior art keywords
alkyl
compound
methoxy
phenyl
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018163513A
Other languages
English (en)
Chinese (zh)
Other versions
CN1466575A (zh
Inventor
克里斯·艾伦·布罗卡
伍恩基·金
凯文·李·麦克拉伦
戴维·伯纳德·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1466575A publication Critical patent/CN1466575A/zh
Application granted granted Critical
Publication of CN1199950C publication Critical patent/CN1199950C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB018163513A 2000-08-09 2001-08-01 作为抗炎剂的喹啉衍生物 Expired - Fee Related CN1199950C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22419600P 2000-08-09 2000-08-09
US60/224,196 2000-08-09

Publications (2)

Publication Number Publication Date
CN1466575A CN1466575A (zh) 2004-01-07
CN1199950C true CN1199950C (zh) 2005-05-04

Family

ID=22839655

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018163513A Expired - Fee Related CN1199950C (zh) 2000-08-09 2001-08-01 作为抗炎剂的喹啉衍生物

Country Status (15)

Country Link
US (2) US7049325B2 (enExample)
EP (1) EP1313707B1 (enExample)
JP (1) JP3930428B2 (enExample)
KR (1) KR20030027016A (enExample)
CN (1) CN1199950C (enExample)
AR (1) AR033554A1 (enExample)
AT (1) ATE367379T1 (enExample)
AU (1) AU2001277560A1 (enExample)
BR (1) BR0113175A (enExample)
CA (1) CA2418832A1 (enExample)
DE (1) DE60129445T2 (enExample)
ES (1) ES2290161T3 (enExample)
MX (1) MXPA03001178A (enExample)
WO (1) WO2002012192A1 (enExample)
ZA (1) ZA200300847B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW591089B (en) * 2001-08-09 2004-06-11 Cheil Ind Inc Slurry composition for use in chemical mechanical polishing of metal wiring
GB0220953D0 (en) * 2002-09-10 2002-10-23 Novartis Ag Organic compounds
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
CN103172697A (zh) * 2005-03-08 2013-06-26 贝林格尔.英格海姆国际有限公司 制备大环化合物的方法
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
KR20120106942A (ko) 2009-10-30 2012-09-27 베링거 인겔하임 인터내셔날 게엠베하 Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
US9383448B2 (en) 2012-07-05 2016-07-05 Deca System Co., Ltd. Golf GPS device with automatic hole recognition and playing hole selection
CN117924243B (zh) * 2024-01-16 2025-09-12 沈阳药科大学 一种喹啉衍生物及其药用组合物和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9018134D0 (en) 1989-09-29 1990-10-03 Ici Plc Heterocyclic derivatives
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
ATE156120T1 (de) 1991-02-07 1997-08-15 Roussel Uclaf Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
GB9311790D0 (en) * 1993-06-08 1993-07-28 Minnesota Mining & Mfg Photothermographic materials
DK122693D0 (da) 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
EP0830133A1 (en) * 1995-04-28 1998-03-25 Takeda Chemical Industries, Ltd. Therapeutic composition for arthritis
DE19638486A1 (de) * 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
DE19638484A1 (de) * 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
US6069151A (en) 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
PA8444901A1 (es) * 1997-01-28 2000-05-24 Hoffmann La Roche Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6479438B2 (en) * 2001-01-04 2002-11-12 Isp Investments Inc. Gel inhibited liquid carrier for a biocide containing a carbodiimide and an emulsifier mixture

Also Published As

Publication number Publication date
ES2290161T3 (es) 2008-02-16
BR0113175A (pt) 2004-02-17
US20020082276A1 (en) 2002-06-27
US7049325B2 (en) 2006-05-23
AU2001277560A1 (en) 2002-02-18
DE60129445D1 (de) 2007-08-30
ZA200300847B (en) 2004-04-30
US20060084677A1 (en) 2006-04-20
US7186840B2 (en) 2007-03-06
CA2418832A1 (en) 2002-02-14
EP1313707B1 (en) 2007-07-18
MXPA03001178A (es) 2003-06-30
WO2002012192A1 (en) 2002-02-14
AR033554A1 (es) 2003-12-26
ATE367379T1 (de) 2007-08-15
KR20030027016A (ko) 2003-04-03
JP3930428B2 (ja) 2007-06-13
EP1313707A1 (en) 2003-05-28
JP2004505951A (ja) 2004-02-26
DE60129445T2 (de) 2008-04-24
CN1466575A (zh) 2004-01-07

Similar Documents

Publication Publication Date Title
CN1263755C (zh) 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
CN1309384C (zh) 具有5－ht6受体亲和性的4－哌嗪基苯磺酰基吲哚
CN1036456C (zh) 氨基取代的吡唑
CN1136197C (zh) 新的哒嗪酮衍生物
CN1234688C (zh) 3－芳酰基吲哚及其作为cb2受体激动剂的应用
CN1261412C (zh) 作为coxⅱ抑制剂的吲哚衍生物
CN1279023C (zh) 吲哚－3－硫衍生物
CN1214007C (zh) 环戊二烯并吲哚、含有这类化合物的组合物及治疗方法
CN1337950A (zh) 2－氧代喹啉化合物及其药物用途
CN1646529A (zh) 咪唑并稠合化合物
CN1656075A (zh) 喹啉衍生物和其作为5－ht6配体的用途
CN1968927A (zh) 对映体选择性制备喹啉衍生物的方法
CN1910157A (zh) 对受体cbi有亲和性的n′－(1,5－二苯基－1h－吡唑－3－基)磺酰胺衍生物
CN1096784A (zh) 含取代4(5)-氨基-1,8-二氨杂萘的治疗剂
CN1244577C (zh) 4－苯基－1－哌嗪基、－哌啶基和－四氢吡啶基衍生物
CN1713908A (zh) 作为5－ht6－受体配体用于治疗中枢神经系统病症的氨基烷氧基吲哚
CN1205704A (zh) 2,7－取代的八氢－吡咯并[1,2－a]吡嗪衍生物
CN1753891A (zh) Ccr－3受体拮抗剂
CN1735618A (zh) 用作ltd4拮抗剂的新型三环衍生物
CN1756753A (zh) 苯并呋喃衍生物
CN1037895A (zh) 杂脂族羧酰胺类化合物
CN1466575A (zh) 作为抗炎剂的喹啉衍生物
CN1159293C (zh) 5-芳酰基萘衍生物
CN87107226A (zh) 内酰胺衍生物及其制备
CN1708478A (zh) 对(磺酰基)芳基和杂芳基类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050504

Termination date: 20090801